Trial Profile
An Open-Label Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Oct 2022
Price :
$35
*
At a glance
- Drugs PCS 499 (Primary)
- Indications Necrobiosis lipoidica
- Focus Adverse reactions
- Sponsors Processa Pharmaceuticals
- 18 Mar 2020 Status changed from active, no longer recruiting to completed.
- 26 Aug 2019 Planned End Date changed from 1 Mar 2021 to 1 Aug 2020.
- 26 Aug 2019 Planned primary completion date changed from 1 Sep 2020 to 1 Feb 2020.